The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines

Clinical Chemistry

Volumn 55, Issue 2, 2009, Pages 219-228

  Mora, Samia ^a   Musunuru, Kiran ^b   Blumenthal, Roger S ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; KINESIOTHERAPY; LIFESTYLE MODIFICATION; LOW DRUG DOSE; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SHORT SURVEY; SMOKING CESSATION; STROKE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT REDUCTION;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS;

EID: 59649099505     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.109728     Document Type: Short Survey

References (38)

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352: 1685-95.
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26.
4. Libby P, Ridker PM. Inflammation and athero- thrombosis from population biology and bench research to clinical practice. J Am Coll Cardiol 2006;48(Suppl):A33-46.
5. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 2006;113:2128-34, discussion 2151.
6. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 2006;113:2135-50, discussion 2150.
7. Pepys MB, Hirschfield GM, Tennent GA, Galli-more JR, Kahan MC, Bellotti V, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006;440:1217-21.
8. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;113:2335-62.
9. Musunuru K, Kral BG, Blumenthal RS, Fuster V, Campbell CY, Gluckman TJ, et al. The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med 2008;5:621-35.
10. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97.
11. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006;145:21-9.
12. Ridker PM, Buring JE, Rifai N, Cook NR Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007; 297:611-9.
13. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008; 118:2243-51.
14. Cook NR. Comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929). Stat Med 2008;27:191-5.
15. Wilson PWF, Pencina M, Jacques P, Selhub J, D'Agostino R, O'Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008;1:92-7.
16. Ridker PM, on behalf of the JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003;108:2292-7.
17. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106: 3143-421.
18. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braun-wald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-5.
19. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
20. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006;47(8 Suppl):C19-31.
21. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
22. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8.
23. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
24. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-44.
25. Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, et al., and Jupiter Trial Study Group. Baseline characteristics of participants in the JUPITER trial, a randomized placebo- controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 2007;100:1659-64.
26. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-207.
27. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
28. Sever PS, DahlofB, Poulter NR, Wedel H, BeeversG, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT- LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
29. Lakoski SG, Cushman M, Blumenthal RS, Kronmal R, Arnett D, D'Agostino RB Jr, et al. Implications of C-reactive protein or coronary artery calcium score as an adjunct to global risk assessment for primary prevention of CHD. Atherosclerosis 2007;193:401-7.
30. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
31. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.
32. Chasman DI, Shiffman D, Zee RY, Louie JZ, Luke MM, Rowland CM, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis [Epub ahead of print 2008 Jul 26].
33. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6.
34. Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation 2007;116:2110-8.
35. Mora S, Lee IM, Buring JE, Ridker PM. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA 2006;295:1412-9.
36. Hamer M. The relative influences of fitness and fatness on inflammatory factors. Prev Med 2007;44:3-11.
37. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor trial. Circulation 2006;114:281-8.
38. Mega JL, Morrow DA, Cannon CP, Murphy S, Cairns R, Ridker PM, et al. Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. J Thromb Thrombolysis 2006;22:71-6.